| 19th week of 2011 patent applcation highlights part 40 |
| Patent application number | Title | Published |
|---|
| 20110111391 | NEWLY IDENTIFIED HUMAN RHINOVIRUS OF HRV-C AND METHODS AND KITS FOR DETECTING HRV-CS - The characterization of a new strain of human rhinovirus of genetic group C(HRV-C) as well as methods and kits for detecting the presence of HRV-C by PCR amplification are provided. | 2011-05-12 |
| 20110111392 | INTEGRATED ENHANCED CHEMILUMINESCENCE BIOSENSORS - A method and apparatus for determining the concentration of an analyte in a sample is provided. This method involves combining enhanced chemiluminescence with microchip capillary electrophoresis or microchip liquid chromatography. | 2011-05-12 |
| 20110111393 | PNA Probes, Mixtures, Methods And Kits Pertaining To The Determination Of Mycoplasma and related Mollicutes - This invention is related to PNA probes, probe sets, mixtures, methods and kits pertaining to the determination of | 2011-05-12 |
| 20110111394 | CTGF AS A BIOMARKER, THERAPEUTIC AND DIAGNOSTIC TARGET - The invention provides CTGF which is associated with the cardiovascular diseases and hematological diseases. The invention also provides assays for the identification of compounds useful in the treatment or prevention of cardiovascular diseases and hematological diseases. The invention also features compounds which bind to and/or activate or inhibit the activity of CTGF as well as pharmaceutical compositions comprising such compounds. The invention also provides CTGF as a biomarker for diseases as cardiovascular diseases and hematological diseases | 2011-05-12 |
| 20110111395 | CD4+CELLS WITH CYTOLYTIC PROPERTIES - The present invention relates to CD4+ T cells, more specifically cytolytic or cytotoxic CD4+ T-cells and methods of obtaining and identifying them. | 2011-05-12 |
| 20110111396 | BIOMARKERS FOR MONITORING THE TREATMENT BY QUINAZOLINONE COMPOUNDS - Provided herein are the biomarkers for monitoring the treatment by quinazolinone compounds. For example, the use of SPARC, p21, and cyclin D1 mRNA levels as biomarkers to predict whether a quinazolinone compound is likely to be successful in treating certain types of cancer, such as NHL is provided. Further, the expression of these genes can be used to monitor progress of treatment effectiveness and patient compliance in cancer patients that are receiving treatment with quinazolinone compounds. | 2011-05-12 |
| 20110111397 | CONNEXIN ALLELE DETECTION ASSAYS - The present invention provides compositions and methods for the detection and characterization of mutations associated with non-syndromic hearing impairment. More particularly, the present invention provides compositions, methods and kits for using invasive cleavage structure assays (e.g. the INVADER assay) to screen nucleic acid samples, e.g., from patients, for the presence of any one of a collection of mutations in the Connexin 26, or gap junction beta 2, gene associated with non-syndromic hearing loss. | 2011-05-12 |
| 20110111398 | NUCLEIC ACID PROBE-BASED DIAGNOSTIC ASSAYS TARGETING SSRA GENES OF PROKARYOTIC AND EUKARYOTIC ORGANISMS - Use of the ssrA gene or tmRNA, an RNA transcript of the ssrA gene, or fragments thereof as target regions in a nucleic acid probe assay for the detection and identification of prokaryotic and/or eukaryotic organisms is described. Nucleotide sequence alignment of tmRNA sequences from various organisms can be used to identify regions of homology and non-homology within the sequences which in turn can be used to design both genus specific and species specific oligonucleotide probes. These newly identified regions of homology and non-homology provide the basis of identifying and detecting organisms at the molecular level. Oligonucleotide probes identified in this way can be used to detect tmRNA in samples thereby giving an indication of the viability of non-viral organisms present in various sample types. | 2011-05-12 |
| 20110111399 | Methods And Compositions Including Diagnostic Kits For The Detection of Staphylococcus Aureus - Methods and compositions, including diagnostic kits, for the detection of | 2011-05-12 |
| 20110111400 | METHOD FOR ENHANCING CHEMICAL SENSITIVITY OR RADIOSENSITIVITY OF CANCER CELLS BY INHIBITING EXPRESSION OF TSPYL5 - Disclosed herein is a method for enhancing sensitivity of cancer cells to compounds or radiation by inhibiting the expression of testis-specific protein, Y-encoded like 5 (TSPYL5). More specifically, because methylation of TSPYL5 protein expressed in lung cancer cell line was inhibited to increase the expression level of the gene, resistance to stress such as radiation or anticancer agents was increased. Because the sensitivity of cancer cells to stress such as radiation or anticancer agents was increased by inhibiting the expression of the TSPYL5 gene to promote the apoptosis of the cells, an anticancer supplement agent containing an inhibitor of the expression or activity of the TSPYL5 gene of the present invention inhibits the growth of cancer cells and enhances the sensitivity to various stresses to maximize the apoptosis. Thus, when used in combination with radiotherapy or chemotherapy, the anticancer supplement agent may be used very usefully for anticancer treatment. | 2011-05-12 |
| 20110111401 | METHOD FOR SEQUENCING NUCLEIC ACID MOLECULES - The present invention is directed to a method of sequencing a target nucleic acid molecule having a plurality of bases. In its principle, the temporal order of base additions during the polymerization reaction is measured on a molecule of nucleic acid, i.e. the activity of a nucleic acid polymerizing enzyme on the template nucleic acid molecule to be sequenced is followed in real time. The sequence is deduced by identifying which base is being incorporated into the growing complementary strand of the target nucleic acid by the catalytic activity of the nucleic acid polymerizing enzyme at each step in the sequence of base additions. A polymerase on the target nucleic acid molecule complex is provided in a position suitable to move along the target nucleic acid molecule and extend the oligonucleotide primer at an active site. A plurality of labelled types of nucleotide analogs are provided proximate to the active site, with each distinguishable type of nucleotide analog being complementary to a different nucleotide in the target nucleic acid sequence. The growing nucleic acid strand is extended by using the polymerase to add a nucleotide analog to the nucleic acid strand at the active site, where the nucleotide analog being added is complementary to the nucleotide of the target nucleic acid at the active site. The nucleotide analog added to the oligonucleotide primer as a result of the polymerizing step is identified. The steps of providing labelled nucleotide analogs, polymerizing the growing nucleic acid strand, and identifying the added nucleotide analog are repeated so that the nucleic acid strand is further extended and the sequence of the target nucleic acid is determined. | 2011-05-12 |
| 20110111402 | KIFS as Modifiers of the RHO Pathway and Methods of Use - Human KIF23 genes are identified as modulators of the RHO pathway, and thus are therapeutic targets for disorders associated with defective RHO function. Methods for identifying modulators of RHO, comprising screening for agents that modulate the activity of KIF23 are provided. | 2011-05-12 |
| 20110111403 | MULTI-PRIMER ASSAY FOR MYCOPLASMA DETECTION - Disclosed is a multi-primer amplification assay, method and kits for detecting | 2011-05-12 |
| 20110111404 | Novel genes and markers in type 2 diabetes and obesity - Genes, SNP markers and haplotypes of susceptibility or predisposition to T2D and subdiagnosis of T2D and related medical conditions are disclosed. Methods for diagnosis, prediction of clinical course and efficacy of treatments for T2D, obesity and related phenotypes using polymorphisms in the risk genes are also disclosed. The genes, gene products and agents of the invention are also useful for monitoring the effectiveness of prevention and treatment of T2D and related traits. Kits are also provided for the diagnosis, selecting treatment and assessing prognosis of T2D. Novel methods for prevention and treatment of metabolic diseases such as T2D based on the disclosed T2D genes, polypeptides and related pathways are also disclosed. | 2011-05-12 |
| 20110111405 | Novel genes and markers in type 2 diabetes and obesity - Genes, SNP markers and haplotypes of susceptibility or predisposition to T2D and subdiagnosis of T2D and related medical conditions are disclosed. Methods for diagnosis, prediction of clinical course and efficacy of treatments for T2D, obesity and related phenotypes using polymorphisms in the risk genes are also disclosed. The genes, gene products and agents of the invention are also useful for monitoring the effectiveness of prevention and treatment of T2D and related traits. Kits are also provided for the diagnosis, selecting treatment and assessing prognosis of T2D. Novel methods for prevention and treatment of metabolic diseases such as T2D based on the disclosed T2D genes, polypeptides and related pathways are also disclosed. | 2011-05-12 |
| 20110111406 | ANTIGEN-BINDING MOLECULE CAPABLE OF BINDING TO TWO OR MORE ANTIGEN MOLECULES REPEATEDLY - The present inventors discovered that antibodies having weaker antigen-binding activity at the early endosomal pH in comparison with that at the pH of plasma are capable of binding to multiple antigen molecules with a single antibody molecule, have long half-lives in plasma, and have improved durations of time in which they can bind to antigen. | 2011-05-12 |
| 20110111407 | METHOD FOR ANALYSING THE EPIGENETIC STATUS OF THE HTRA 1 GENE IN A BIOLOGICAL SAMPLE - The invention relates to a method for analysing a biological sample, wherein the epigenetic status of at least one section of the HtrA 1 gene is analysed. Furthermore, diagnostic kits as well as a screening method for identifying a molecule which inhibits the binding of an epigenetic factor to at least one section of the HtrA1 gene are provided. | 2011-05-12 |
| 20110111408 | METHODS AND COMPOSITION FOR SECRETION OF HETEROLOGOUS POLYPEPTIDES - The present invention relates generally to the fields of molecular biology and protein technology. More specifically, the invention concerns signal sequences for the secretion of heterologous polypeptide from bacteria. The invention also concerns recombinant polypeptides and uses thereof. | 2011-05-12 |
| 20110111409 | METHODS FOR DEPLETING RNA FROM NUCLEIC ACID SAMPLES - The invention relates to methods of depleting RNA from a nucleic acid sample. The RNA may be any RNA, including, but not limited to, rRNA, tRNA, and mRNA. The method is useful for depleting RNA from a nucleic acid sample obtained from a fixed paraffin-embedded tissue (FPET) sample. The method may also be used to prepare cDNA, in particular, a cDNA library for further analysis or manipulation. | 2011-05-12 |
| 20110111410 | STABILIZATION OF RNA IN INTACT CELLS WITHIN A BLOOD SAMPLE - A method for preserving and processing nucleic acids located within a blood sample is disclosed, wherein a blood sample containing nucleic acids is treated to reduce both blood cell lysis and nuclease activity within the blood sample. The treatment of the sample aids in increasing the integrity and amount of cellular nucleic acids that can be identified and tested while avoiding contamination of the isolated nucleic acids with cell-free nucleic acids. | 2011-05-12 |
| 20110111411 | Protein-Responsive RNA Control Devices and Uses Thereof - The invention described herein relates to an RNA-based control device that senses the presence and/or concentration of at least one protein ligand, preferably through its protein-binding aptamer domain, and regulates a target gene expression through alternative splicing of the target gene in which the RNA-based control device is integrated. The device has uses in therapeutic as well as diagnostic applications. | 2011-05-12 |
| 20110111412 | Uses of Parylene Membrane Filters - The invention provides parylene membrane filters, filter devices and methods of making them and using them in the mechanical separation of cells and particles by size. The provision of parylene membrane filters with high figures of merit and finely controlled hole sizes allows the separation of cells and particles in a variety of biological and other fluids according to sizes. | 2011-05-12 |
| 20110111413 | METHOD OF OPTIMIZING CODON USAGE THROUGH DNA SHUFFLING - The present invention relates to codon optimization utilizing DNA shuffling. A method of producing gene sequences optimized for a desired functional property is described involving synthesizing a library of parental codon variant genes encoding some or all codon choices at some or all amino acid positions of a gene, reassorting the variant codons among the parental codon variant genes using DNA shuffling thereby forming progeny codon variant genes, expressing the progeny codon variant genes in a host; and screening or selecting for progeny codon variant genes encoding a desired functional property. | 2011-05-12 |
| 20110111414 | Detecting Agent and Therapeutic Agent for Highly Malignant Breast Cancer - A detection agent for high malignancy breast cancer includes an antibody against collagen XIV, or a variant or derivative or fragment of the antibody. A therapeutic agent for high malignancy breast cancer includes a conjugate of an anticancer drug and an antibody against that protein, or a variant or derivative or fragment thereof. Accordingly, it is possible to easily and accurately detect and diagnose high malignancy breast cancer. | 2011-05-12 |
| 20110111415 | MULTI-STAGE NUTRIGENOMIC DIAGNOSTIC FOOD SENSITIVITY TESTING IN ANIMALS - A multi-stage method for diagnosing an immunologic food sensitivity or intolerance in a companion animal. Firstly a saliva or blood spot or other non-serum bodily fluid sample is collected. The screening the saliva or blood spot or other non-serum bodily fluid sample detects the presence of at least one of IgA or IgM antibody to a particular food ingredient or composition. An immunologic food sensitivity or intolerance based on the presence of the antibody is diagnosed. Secondly a blood sample is collected and serum from the sample is screened to detect the semi-quantitative or quantitative presence of at least one of an IgA, IgM or IgG antibody or immune complex to a particular food ingredient or composition. An immunologic food sensitivity or intolerance based on the presence of the antibody or immune complex is diagnosed. Thirdly, a biologically active nutrient in relation to the animal from a molecular dietary signature is determined. The molecular dietary signature for the animal is a variation of expression of a set of genes, proteins or metabolites which may differ for the genotype of each animal. | 2011-05-12 |
| 20110111416 | Peptide Nucleic Acid Probes, Kits and Methods for Expression Profiling of Micrornas - Disclosed are peptide nucleic acid (PNA) probes, a kit and a method for expression profiling of microRNAs (miRNAs), which play an important role in regulation of expression of genes encoding proteins. | 2011-05-12 |
| 20110111417 | METHODS AND KITS FOR MONITORING THE EFFECTS OF IMMUNOMODULATORS ON ADAPTIVE IMMUNITY - The invention provides for noninvasive assessment of immunocompetence in various situations, for example, when modified by disease or by immunomodulators. The assessment determines the functional activity of germinal centers via measuring levels of immunogolublin isotype class switching. The invention provides for assessment of therapeutic efficacy of immunomodulators and for selection of treatment regimens. The invention also provides for determining the risk or susceptibility to adverse events upon receipt of therapy. Compositions, kits and methods are described herein. | 2011-05-12 |
| 20110111418 | USE OF IRON-RELATED PATHWAYS AND GENES FOR TREATMENT AND DIAGNOSIS OF PARKINSON'S DISEASE - A collection of genetic variants having susceptability to, or protection from, Parkinson's Disease is provided. The variants are useful in method of diagnosing, prognosing, and treating Parkinson's Disease and related conditions | 2011-05-12 |
| 20110111419 | Copy Number Variations Predictive of Risk of Schizophrenia - The present invention relates to genomic copy number variations as risk factors for schizophrenia. The invention provides methods and kits for risk management of schizophrenia, by assessing such copy number variations in the genome of individuals. | 2011-05-12 |
| 20110111420 | Corn Event MIR604 - A novel transgenic corn event designated MIR604, is disclosed. The invention relates to DNA sequences of the recombinant constructs inserted into the corn genome and of genomic sequences flanking the insertion site that resulted in the MIR604 event. The invention further relates to assays for detecting the presence of the DNA sequences of MIR604, to corn plants and corn seeds comprising the genotype of MIR604 and to methods for producing a corn plant by crossing a corn plant comprising the MIR604 genotype with itself or another corn variety | 2011-05-12 |
| 20110111421 | Gene Expression Markers for Colorectal Cancer Prognosis - A method of predicting clinical outcome in a subject diagnosed with colorectal cancer comprising determining evidence of the expression of one or more predictive RNA transcripts or their expression products in a biological sample of cancer cells obtained from the subject. | 2011-05-12 |
| 20110111422 | SENSOR PROTEINS AND ASSAY METHODS - The present invention relates to biosensors. In some embodiments, the biosensors are modified ligand binding molecules. In some embodiments, the modified ligand binding molecule is a phosphate binding protein (PBP). In some embodiments, the modified ligand binding molecules are labeled to be capable of RET, e.g., comprising a donor and acceptor moiety. In some embodiments of the invention, there is a detectable change in RET (e.g., FRET) when the modified ligand binding molecule binds and/or releases the ligand (e.g., phosphate). The invention also provides related methods, reactions and assays. | 2011-05-12 |
| 20110111423 | Demethylated and / or oxidized membrane DNA - A process for the preparation of oxidized and/or demethylated antigens comprising the steps of
| 2011-05-12 |
| 20110111424 | ANALYSIS OF UBIQUITINATED POLYPEPTIDES - The invention relates to antibody reagents that specifically bind to peptides carrying a ubiquitin remnant from a digested or chemically treated biological sample. The reagents allow the technician to identify ubiquitinated polypeptides as well as the sites of ubiquitination on them. The reagents are preferably employed in proteomic analysis using mass spectrometry. The antibody reagents specifically bind to the remnant of ubiquitin (i.e., a diglycine modified epsilon amine of lysine) left on a peptide which as been generated by digesting or chemically treating ubiquitinated proteins. The inventive antibody reagents' affinity to the ubiquitin remnant does not depend on the remaining amino acid sequences flanking the modified (i.e., ubiquitinated) lysine, i.e., they are context independent. | 2011-05-12 |
| 20110111425 | ENHANCED IMMUNOASSAY SENSOR - Disclosed herein are devices for detecting the presence of a target analyte in a fluid sample. The biosensor device can comprise at least a reaction chamber and a detection chamber. The device can comprise a amplifying mechanism such that one target analyte molecule present in the fluid sample can lead to generation/activation of multiple detection agent molecules, and therefore, an amplified signal. Also disclosed are the methods of manufacturing and using such a biosensor device. | 2011-05-12 |
| 20110111426 | METHOD OF BIOASSAYING YOKUKANSAN - The invention intends to find out a bioassay system with an in-vitro test capable of ensuring the higher quality of yokukansan, and provides a bioassay method for yokukansan, comprising competitively reacting a labeled ligand and yokukansan with cells or cell membranes expressing glutamate receptors, measuring the binding activity of yokukansan, and evaluating the pharmacological activity value of yokukansan from the measurement value. | 2011-05-12 |
| 20110111427 | BIOMARKER FOR THE ESTIMATION OF ACUTE RENAL DISORDER AND PROGNOSIS OF THE DISORDER, AND USE OF THE BIOMARKER - To provide a novel biomarker that is useful for prediction of early onset of acute kidney injury, estimation of prognosis associated with a renal function, and differentiation of acute kidney injury. Furthermore, to provide use of the novel biomarker. Midkine is used as a biomarker. The determination of a possibility of the onset of acute kidney injury, estimation of prognosis associated with a renal function or differentiation of an acute kidney injury are carried out based on the detection result of the urinary midkine. | 2011-05-12 |
| 20110111428 | Method for Sensing a Chemical - The present invention relates to a method for detecting an analyte ( | 2011-05-12 |
| 20110111429 | FLUORESCENT CARBAZOLE COMPOUNDS FOR CANCER DIAGNOSIS - A compound of formula (I): | 2011-05-12 |
| 20110111430 | METHOD FOR DIAGNOSING LIVER FIBROSIS - Provided herein are methods and devices for nonsurgically predicting, diagnosing, and monitoring liver fibrosis in an individual. Methods utilize biomarkers, age and sex to determine a diagnostic score. The diagnostic score is then used to predict, diagnose, or assess liver fibrosis in the individual. | 2011-05-12 |
| 20110111431 | METHOD FOR IDENTIFYING PRE-NEOPLASTIC AND/OR NEOPLASTIC STATES IN MAMMALS - The present invention relates to methods of identifying pre-neoplastic and/or neoplastic states in mammals and in particular to a method for identifying pre-neoplastic and neoplastic cells in tissues and body fluids, based on differential expression of purinergic receptors in these cells. | 2011-05-12 |
| 20110111432 | DIAGNOSTIC METHOD FOR PEANUT ALLERGY - The present invention provides novel methods and tools to differentiate between true allergy and false positive allergy tests. In particular, parameters that can be statistically associated with true peanut allergy have been identified. These include wheal size in response to a skin prick test and total IgE. Further parameters may be measured for greater certainty. | 2011-05-12 |
| 20110111433 | PIEZOELECTRICAL CHARACTERIZATION OF MATERIALS - One aspect of the disclosure is a method of characterizing a surface. In an exemplary embodiment, the method includes: (a) positioning a piezoelectric sensor near the surface; (b) obtaining by the sensor a resonant acoustic profile (RAP) of the surface; and (c) analyzing the obtained RAP to characterize the surface. The piezoelectric sensor has an interacting layer, which is adapted for binding to the surface to be characterized. In one embodiment, the characterized surface and the interacting layer are of about the same size. | 2011-05-12 |
| 20110111434 | COLON STEM CELLS ASSOCIATED WITH COLITISAND COLORECTAL CANCER AND METHODS OF USE - The disclosure provides methods of isolating and propagating self-renewing colonic stem/progenitor cells (CS/PCs) that express aldehyde dehydrogenase (ALDH1), from colon cancer and colitis tissues, as well as from normal colon tissue, methods of identifying agents for modulating the proliferative status of such cells, an methods of screening patients having colitis for an increased risk of colorectal cancer. Novel methods of adherent cell culture propagation of CS/PC involving use of colon-specific fibroblastic stromal cells (CFSt) {i.e. the “niche” cells) as support cells (e.g., “feeder cells”). The present disclosure encompasses an isolated mammalian pluripotent colon epithelial stem/progenitor cell (CS/PC), or a population of said cells, where each CS/PC may comprise a detectable marker, where the detectable marker is aldehyde dehydrogenase 1 (ALDH1), and where the isolated population of mammalian pluripotent CS/PCs is substantially free of cells that do not have the detectable ALDH 1 marker. The disclosure encompasses further provides methods for determining the prognosis for a patient for developing a colon cancer, the method detecting the presence of at least one marker in a tissue section from a patient, the marker or plurality of markers indicating the presence of a pluripotent colon epithelial stem/progenitor cells and indicating the prognosis of the patient for developing a colon cancer. | 2011-05-12 |
| 20110111435 | Detecting Cell Surface Markers - In one aspect, the present invention provides a method for detecting an expression level of a cell surface marker in a sample, comprising staining the sample with a reagent that labels the cell surface marker; obtaining an image of the stained sample; and determining a value for continuity of cell surface staining in the image, wherein the value is indicative of the expression level. | 2011-05-12 |
| 20110111436 | METHODS FOR ASSESSING CANCER FOR INCREASED SENSITIVITY TO 10-PROPARGYL-10-DEAZAAMINOPTERIN - Sensitivity of a patient's cancer to treatment with 10-propargyl-10-deazaaminopterin is assessed and patients are selected for treatment of cancer with 10-propargyl-10-deazaaminopterin, by determining the amount of a selected polypeptide expressed by the cancer and comparing the amount with the amount of the selected polypeptide expressed by a reference cancer. The polypeptide includes a member of a folate pathway polypeptide within a cell and may include at least one of reduced folate carrier-1 enzyme (RFC-1), dihydrofolate reductase (DHFR), folylpoly-gamma-glutamate synthetase (FPGS), thymidylate synthase (TS), γ-glutamyl hydrolase (GGH), and glycinamide ribonucleotide formyltransferase (GARFT). | 2011-05-12 |
| 20110111437 | Biomarkers For Prognosis of Pulmonary Diseases - The present invention relates to biomarkers that may be used to evaluate the prognoses of patients suffering from pulmonary diseases and assist in the determination of appropriate therapeutic regimens. It is based, at least in part, on the discovery that a number of T-cell antigens are differentially expressed in chronic lung disease patients depending on the prognosis of the patient. Non-limiting examples of these antigens include CD28, CD4, CD25, CD45, CD27 and CCR7 and combinations thereof. Use of these biomarker antigens, optionally in conjunction with pulmonary function tests, provides an indication of which patients are likely to suffer a severely adverse outcome within the year and/or be refractory to treatment. | 2011-05-12 |
| 20110111438 | METHOD AND DEVICE FOR IMMUNOASSAY - The present invention relates to a method and a device for determining a concentration of a biological active substance in a sample by the means of an enzyme-linked immunosorbent assay (ELISA). The device comprises a solid support within a tubing ( | 2011-05-12 |
| 20110111439 | Elevation of Induced Heat Shock Proteins in Patient's Cerebral Spinal Fluid: A Biomarker of Risk/Onset of Ischemia and/or Paralysis in Aortic Surgery - Provided are methods for intra-operatively predicting, detecting or diagnosing the risk or onset of spinal cord ischemia and/or associated permanent paralysis in a patient, based upon the stress-induced elevation of levels of heat shock proteins, specifically HSP70 and/or HSP27 in the cerebral spinal fluid of the patient, as measured during thoracic-aorta surgery, particularly thoracic aneurysm repair surgery, that will permit intra-operative medical intervention to try to prevent or attenuate severe, and often fatal, complications. Further provided are kits, assay devices and methods of analyzing biomarker data for use in pre-, intra- or post-operatively detecting the stress-induced elevations of the measured levels of HSP70 and/or HSP27, and the biomarker itself. | 2011-05-12 |
| 20110111440 | ELISA KIT FOR DETECTING LINCOMYCIN - The present invention provides an ELISA kit for detecting lincomycin comprising a coating antigen and an enzyme labeled reagent, wherein the coating antigen is selected from the group consisting of a lincomycin hapten-carrier protein conjugate, a lincomycin antibody and a lincomycin anti-antibody; when the coating antigen is the lincomycin hapten-carrier protein conjugate, the enzyme labeled reagent is an enzyme-labeled lincomycin anti-antibody; when the coating antigen is the lincomycin antibody, the enzyme labeled reagent is an enzyme-labeled lincomycin hapten-carrier protein conjugate; and when the coating antigen is the lincomycin anti-antibody, the enzyme labeled reagent is an enzyme-labeled lincomycin hapten-carrier protein conjugate; and the lincomycin hapten is obtained through the condensation reaction between lincomycin and succinic anhydride. The ELISA kit according to the present invention can be used for detecting the content of lincomycin remained in a sample such as an animal tissue (muscle, liver), honey, etc. | 2011-05-12 |
| 20110111441 | METHOD AND KIT FOR MEASUREMENT OF ENDOTOXIN LEVEL - The present invention provides a method comprising allowing a reaction of a sample, a reagent containing Factor C, which can be activated by binding with endotoxin, and a synthetic luminescent substrate comprising a luminescent substrate bound to a peptide, for release of the luminescent substrate from the synthetic luminescent substrate, allowing a luminescent enzyme to act on the luminescent substrate released in the luminescent substrate release step, for measurement of the luminescence intensity, and quantifying the level of endotoxin in the sample based on a measured value obtained in the luminescence measuring step, the method enabling endotoxin to be simply and quickly measured at a level that cannot be detected in conventional methods for endotoxin measurement, without use of any dedicated measuring device. | 2011-05-12 |
| 20110111442 | Intein-modified enzymes, their production and industrial applications - A method of predicting an intein insertion site in a protein that will lead to a switching phenotype is provided. The method includes identifying a plurality of C/T/S sites within the protein; selecting from the plurality of C/T/S/ sites those that are ranked 0.75 or higher by a support vector machine, within ten angstroms of the active site of the protein, and at or near a loop-β-sheet junction or a loop-α-helix junction. A method of controlling protein activity and hosts including proteins with controlled activity are also provided. Also, intein modified proteins and plants containing intein modified proteins are provided. | 2011-05-12 |
| 20110111443 | APPARATUS FOR AUTO-PRETREATING SUGAR CHAIN - To provide an autoanalyzer for analyzing a sugar chain contained in a biological sample, in particular, serum. Namely, it is intended to provide a method of analyzing a sugar chain in a sample, which comprises the following steps: A) the sugar chain-releasing step of releasing the sugar chain in the sample; B) the detection sample-preparing step of preparing the released sugar chain for detection; and, in the case of conducting mass spectrometry using a plate, C) the step of forming a plate for the mass spectrometry having the captured sugar chain dotted thereon which comprises the step of providing the tagged sugar chain sample solution obtained in the step B) on a collection plate; and, if required, the step of conducting an operation in a solid phase support-enclosed plate to form the plate for mass spectrometry; and D) the step of analyzing the sugar chain to be assayed. | 2011-05-12 |
| 20110111444 | Method of Screening for Compounds which Affect the Processing of EphA4 by Gamma-Secretase - The present invention provides a method of screening for compounds which affect the processing of EphA4 by γ-secretase, comprising the following steps: (i) contacting a first biological composition containing γ-secretase or a biologically active fragment thereof with a second biological composition containing EphA4 in the presence and absence of a candidate compound; (ii) measuring the cleavage of the EphA4 in the presence and absence of the candidate compound; (iii) selecting those candidate compounds which affect the cleavage of the EphA4 by γ-secretase; and (iv) identifying the candidate compounds selected in step (iii) as compounds which affect the processing of EphA4 by γ-secretase. | 2011-05-12 |
| 20110111445 | Peptide for Determining Actin Structures in Living Cells - The present invention relates to novel peptides capable of binding to action. The peptides are useful in methods for detecting actin in vitro or in living cells. | 2011-05-12 |
| 20110111446 | THIOL DETECTION METHOD - It is an object of the present invention to provide: a novel thiol-detecting reagent, which can be used in vivo and which solves the problem regarding the generation of background fluorescence due to hydrolysis; and a method for detecting thiol using the aforementioned reagent. The present invention provides a compound represented by the following formula (1): | 2011-05-12 |
| 20110111447 | ONE TO ONE IDENTIFICATION SYSTEM - The present invention relates to a system arranged for assisting secure handling of cells in order to minimize the risk of handling mistakes resulting in mix-up of cell samples. The system allows for one to one identification of cells during a whole culturing period. This is obtained by providing a culturing system with loading/exit control means which ensures that only one device is capable of being loaded/removed at a time. | 2011-05-12 |
| 20110111448 | DEVICE COMPRISING A FIELD OF TIPS USED IN BIOTECHNOLOGY APPLICATIONS - A method for manufacturing a device including a field of micrometric tips, including forming a polycrystalline layer on a support; performing an anisotropic plasma etching of all or part of the polycrystalline layer by using a gas mixture including chlorine and helium, whereby tips are formed at the surface of the polycrystalline layer. | 2011-05-12 |
| 20110111449 | IN VITRO DETERMINATION OF ANALYTE LEVELS WITHIN BODY FLUIDS - A reagentless whole-blood analyte detection system that is capable of being deployed near a patient has a source capable of emitting a beam of radiation that includes a spectral band. The whole-blood system also has a detector in an optical path of the beam. The whole-blood system also has a housing that is configured to house the source and the detector. The whole-blood system also has a sample element that is situated in the optical path of the beam. The sample element has a sample cell and a sample cell wall that does not eliminate transmittance of the beam of radiation in the spectral band. | 2011-05-12 |
| 20110111450 | Diagnostic Device and Method - A method of separating a cell-containing sample into a substantially cell-depleted portion, and a cell-containing portion comprising at least one of a stem cell, a lymphocyte, and a leukocyte comprises a step in which the sample is received in a vessel with at least one flexible wall. In another step, an additive and particles are added to the sample, wherein the additive substantially binds to the at least one of the stem cell, lymphocyte, and leukocyte, and the particles and wherein the particles substantially bind to the at least one of the stem cell, lymphocyte, and leukocyte, and the additive, thereby producing a cell-containing network. In a further step, the network is separated from the substantially cell-depleted portion by applying a magnetic force. | 2011-05-12 |
| 20110111451 | Gross Hematuria Evaluator and Methods for Making and Using Same - A device for evaluating the blood content in a plurality of media may include a display having a plurality of columns, each column having a plurality of color-block rows, where the colors are created by diluting blood in the respective medium to obtain a color, and then substantially matching that color with a row in the column. Additionally or alternatively, the columns may represent blood diluted in the same sample, but observed at different times. The display may include gaps between columns to accept a catheter in which the sample to be analyzed is placed and a legend identifying the medium and blood dilution for each column and row, as well as the time of aging, if any, for a column. | 2011-05-12 |
| 20110111452 | METHOD AND KIT FOR DIAGNOSIS OF MALE FERTILITY - A method and kit are disclosed for the diagnosis of male fertility. | 2011-05-12 |
| 20110111453 | Compositions for saccharification of cellulosic material - The present invention relates to enzyme compositions for high temperature saccharification of cellulosic material and to uses thereof. | 2011-05-12 |
| 20110111454 | ENGINEERED VERSIONS OF CgtB (Beta-1,3 GALACTOSYLTRANSFERASE) ENZYMES, WITH ENHANCED ENZYMATIC PROPERTIES - CgtB proteins with enhanced beta 1,3-galactosaminyltransferase activity, nucleic acids that encode the CgtB proteins and methods for use of the CgtB proteins. | 2011-05-12 |
| 20110111455 | Polymer-Von Willebrand Factor-Conjugates - The present invention relates to a proteinaceous construct (also designated as polymer-VWF-conjugate) comprising plasmatic and/or recombinant von Willebrand factor (VWF), said VWF being bound to at least one physiologically acceptable polymer molecule, as well as to a complex between said proteinaceous construct and at least one factor VIII (FVIII) protein. The physiologically acceptable polymer molecule can be, for instance, polyethylene glycol (PEG) or polysialic acid (PSA). Further the present invention relates to methods for prolonging the in vivo-half-life of VWF or FVIII in the blood of a mammal having a bleeding disorder associated with functional defects of or deficiencies of at least one of FVIII or VWF. | 2011-05-12 |
| 20110111456 | PROCESSING BIOMASS - Biomass (e.g., plant biomass, animal biomass, and municipal waste biomass) is processed to produce useful products, such as fuels. For example, systems can use feedstock materials, such as cellulosic and/or lignocellulosic materials and/or starchy or sugary materials, to produce ethanol and/or butanol, e.g., by fermentation. | 2011-05-12 |
| 20110111457 | METHODS FOR MICROBIAL PRODUCTION OF TERPENOIDS - The invention relates to recombinant expression of terpenoid synthase enzymes and geranylgeranyl diphosphate synthase (GGPPS) enzymes in cells and the production of diterpenoids. | 2011-05-12 |
| 20110111458 | INDUSTRIALLY USEFUL MICROORGANISM - An object of the present invention is to provide an | 2011-05-12 |
| 20110111459 | COMPOSITIONS AND METHODS FOR NUCLEIC ACID DELIVERY - Disclosed herein are methods and compositions for preparing a lipid encapsulated nucleocapsid delivery composition capable of delivering a nucleic acid to a mammalian cell. The nucleocapsid delivery compositions disclosed herein are useful for large-scale protein production, expression of genes in a mammalian expression system, and/or pharmaceutical production of a recombinant protein for treatment of an individual. In addition, the nucleocapsid delivery compositions can be used to treat an individual to replace a gene or gene product, or alternatively to inhibit a gene product using an RNA interference molecule. | 2011-05-12 |
| 20110111460 | Method for Making Mature Insulin Polypeptides - The invention is related to a method for making human insulin analogues by culturing an fungi cell comprising a DNA vector encoding a precursor for human insulin analogue, wherein the said precursor comprises a connecting peptide flanked with cleavage sites at both junctions with the A- and the B-chain of the insulin peptide, respectively said cleavage sites being cleaved within the fungi cell allowing the cell to secrete high amount of correctly processed, mature two chain human insulin analogue to the culture media. | 2011-05-12 |
| 20110111461 | Antigen Binding Molecules that Bind EGFR, Vectors Encoding Same, and Uses Thereof - The present invention relates to antigen binding molecules (ABMs). In particular embodiments, the present invention relates to recombinant monoclonal antibodies, including chimeric, primatized or humanized antibodies specific for human EGFR. In addition, the present invention relates to nucleic acid molecules encoding such ABMs, and vectors and host cells comprising such nucleic acid molecules. The invention further relates to methods for producing the ABMs of the invention, and to methods of using these ABMs in treatment of disease. In addition, the present invention relates to ABMs with modified glycosylation having improved therapeutic properties, including antibodies with increased Fc receptor binding and increased effector function. | 2011-05-12 |
| 20110111462 | Composition and Method for Synthesizing a Deoxyribonucleotide Chain Using a Double Stranded Nucleic Acid Complex with a Thermostable Polymerase - The present invention relates to the field of molecular biology, and more particular, to a nucleic acid construct for use in amplification processes. More precisely, the invention enhances the specificity of amplification of nucleic acids by means of a double stranded oligonucleotide modified with a molecule having the ability to prevent extension of the double stranded nucleic acid. | 2011-05-12 |
| 20110111463 | LYSIS AND REVERSE TRANSCRIPTION FOR MRNA QUANTIFICATION - The present invention is directed to a method for performing an RT-PCR for amplifying a target RNA including the steps of (i) cultivation of a population of adherent cells in a cell culture vessel (ii) lysis of the population of adherent cells which is supposed to contain the target RNA in the sample vessel with a lysis buffer comprising between 0.05 M and 1 M of a chaotropic agent (iii) adding reagents to the sample vessel which are necessary to perform a reverse transcription reaction such that the the chaotropic agent is present in a concentration of about 10 to 60 mM in the sample vessel, and reverse transcribing the target RNA and (iv) amplifying the first strand cDNA by means of subjecting the sample to multiple cycles of a thermocycling protocol. | 2011-05-12 |
| 20110111464 | METHODS AND COMPOSITIONS FOR CLONING NUCLEIC ACID MOLECULES - The present invention is directed generally to methods facilitating the cloning of nucleic acid molecules. In particular, the invention relates to the use of polymerase inhibitors, including but not limited to anti-polymerase antibodies (such as anti-Taq antibodies) and fragments thereof, to inactivate residual polymerase activity remaining after the amplification (particularly via PCR) of a target nucleic acid molecule. The invention further provides compositions, particularly storage-stable compositions, comprising one or more components, such as one or more restriction endonucleases and one or more polymerase inhibitors, that are useful in cloning amplified or synthesized nucleic acid molecules by the above-described methods. The invention also relates to nucleic acid molecules produced by these methods, and to genetic constructs (such as vectors) and host cells comprising these nucleic acid molecules. | 2011-05-12 |
| 20110111465 | Pseudopterosin-producing bacteria and methods of use - Clonal strains of bacteria derived from | 2011-05-12 |
| 20110111466 | Microorganisms for Producing L-Amino Acids and Process for Producing L-Amino Acids Using Them - The present invention relates to a transformed microorganism producing an L-amino acid using sucrose as a main carbon source, and a method for producing an L-amino acid using the same. | 2011-05-12 |
| 20110111467 | Method for Preparation of Carbamic Acid (R)-1-Aryl-2-Tetrazolyl-Ethyl Ester - Disclosed is a method for the preparation of carbamic acid (R)-1-aryl-2-tetrazolyl-ethyl esters, comprising the enantioselective enzyme reduction of a 1-aryl-2-tetrazolyl-ethyl ketone to form a (R)-1-aryl-2-tetrazolyl-ethyl alcohol and the carbamation of said alcohol. | 2011-05-12 |
| 20110111468 | VARIANT LOVD POLYPEPTIDES AND THEIR USES - The present disclosure provides acyltransferases useful for synthesizing therapeutically important statin compound | 2011-05-12 |
| 20110111469 | PROCESS FOR THE PRODUCTION OF N-ACYL-PHOSPHATIDYL-ETHANOLAMINE - The document describes a process for the preparation of N-Acyl-Phosphatidyl-Ethanolamine of formula (I) on an industrial scale, In which R | 2011-05-12 |
| 20110111470 | Methods and Compositions for the Recombinant Biosynthesis of Fatty Acids and Esters - The present disclosure identifies methods and compositions for modifying photoautotrophic organisms, such that the organisms efficiently convert carbon dioxide and light into compounds such as esters and fatty acids. In certain embodiments, the compounds produced are secreted into the medium used to culture the organisms. | 2011-05-12 |
| 20110111471 | NOVEN THERMOSTABLE GLUCONATE DEHYDRATASE AND USE THEREOF - The present invention relates to a novel thermostable gluconate dehydratase from the thermoacidophilic archaeon | 2011-05-12 |
| 20110111472 | FERMENTIVE PRODUCTION OF FOUR CARBON ALCOHOLS - Methods for the fermentative production of four carbon alcohols is provided. Specifically, butanol, preferably isobutanol is produced by the fermentative growth of a recombinant bacterium expressing an isobutanol biosynthetic pathway. | 2011-05-12 |
| 20110111473 | YEAST CELLS AND METHODS FOR INCREASING ETHANOL PRODUCTION - Provided herein are methods for producing ethanol using yeast to ferment pretreated solid lignocellulosic materials such as pretreated solid lignocellulosic materials obtained from softwoods like pine. The pretreated solid lignocellulosic material is present at a concentration of at least 12% solids, and at least 30 grams ethanol per liter, preferably at least 40 grams ethanol per liter, are produced within 48 hours. In some aspects, the pretreated solid lignocellulosic material is not detoxified prior to the fermentation. Also provided herein are yeast that ferment a composition that includes pretreated solid lignocellulosic material at a concentration of at least 12% solids to yield at least 30 grams ethanol per liter, preferably at least 40 grams ethanol per liter, in 48 hours. Further provided herein are methods for acclimatizing yeast. | 2011-05-12 |
| 20110111474 | METHOD FOR PRODUCING ETHANOL BY FERMENTATION FROM LIGNOCELLULOSIC BIOMASS - The description relates to a method of producing bioethanol by separating lignin from a crushed lignocellulose biomass and obtaining cellulose and, if required, hemicellulose and additionally processing the cellulose or the mixture of cellulose and hemicellulose to form sugars and subsequently form bioethanol. The method is characterised in that crushed lignocelluloses biomass is treated with an alkanolamine for extracting the lignin therein, the lignin solution is separated, the residue containing cellulose/hemicellulose is converted to sugars without drying, and the sugars are fermented to obtain bioethanol. The raw cellulose (cellulose/hemicellulose), owing to its high reactivity, can easily be converted into sugar, which can be fermented to form bioethanol. | 2011-05-12 |
| 20110111475 | Biological/Electrolytic Conversion of Biomass to Hydrocarbons - Hydrocarbon and hydrogen fuels and other products may be produced by a process employing a combination of fermentation and electrochemical stages. In the process, a biomass contained within a fermentation medium is fermented with an inoculum comprising a mixed culture of microorganisms derived the rumen contents of a rumen-containing animal. This inoculated medium is incubated under anaerobic conditions and for a sufficient time to produce volatile fatty acids. The resultant volatile fatty acids are then subjected to electrolysis under conditions effective to convert said volatile fatty acids to hydrocarbons and hydrogen simultaneously. The process can convert a wide range of biomass materials to a wide range of volatile fatty acid chain lengths and can convert these into a wide range of biobased fuels and biobased products. | 2011-05-12 |
| 20110111476 | BLOOD CELL SORTING METHODS AND SYSTEMS - The invention relates to methods of isolating white blood cells (WBCs) from a sample, e.g., whole blood, using magnetic particles that specifically bind to WBCs and a series of specific steps and conditions. The methods can include one or more of decreasing the viscosity of the sample prior to WBC isolation, agitating the sample at specified frequencies, and/or using a sample container arranged such that all of the sample is placed in close proximity (e.g., within 5, 2, 1, or 0.5 mm) to the source of the magnetic field. The new methods provide for isolation of WBC preparations with high yield, purity, and viability. The methods are designed for compatibility with automation protocols for rapid processing of multiple samples. | 2011-05-12 |
| 20110111477 | LONG ACTING FORMULATION OF BIOPHARMACEUTICAL - The invention relates to a long-acting formulation of biopharmaceutical, more specifically an aptamer therapeutics. A branched PEGylated aptamer or a hyaluronic acid (HA) derivative of which degradation in vivo is regulated is linked by the bioconjugation with biopharmaceutical to produce the long-action formulation. | 2011-05-12 |
| 20110111478 | Amides as Inhibitors of Human Secreted Phospholipase A2 - Methods and compounds useful for inhibiting a phospholipase A | 2011-05-12 |
| 20110111479 | Botulinum Neurotoxin Serotype B Activatable Botulinum Neurotoxin Serotype Bs - The specification discloses modified Clostridial toxins comprising a Clostridial toxin substrate cleavage site located within the di-chain loop region; polynucleotide molecules encoding such modified Clostridial toxins comprising a Clostridial toxin substrate cleavage site located in the di-chain loop region; and method of producing modified Clostridial toxins comprising Clostridial toxin substrate cleavage site located within the di-chain loop region. | 2011-05-12 |
| 20110111480 | Telomelysin/GFP-expressing recombinant virus - The present invention provides a reagent for cancer cell detection or cancer diagnosis. The present invention relates to a reagent for cancer cell detection, comprising a recombinant virus where a replication cassette comprising a promoter from human telomerase, an E1A gene, an IRES sequence and an E1B gene in this order is integrated in E1 region of the viral genome and a labeling cassette comprising a gene encoding a labeling protein and a promoter capable of regulating the expression of the gene encoding the labeling protein is integrated in E3 region of the viral genome. | 2011-05-12 |
| 20110111481 | ENABLING THE USE OF LONG dsRNA FOR GENE TARGETING IN MAMMALIAN AND OTHER SELECTED ANIMAL CELLS - The present invention provides a method of enabling the use of long dsRNA for gene silencing in mammalian cells through bacteria, preferably non-pathogenic or therapeutic strains of bacteria. DNA that encodes long double-strand RNAs are transformed into bacteria and processed in the bacterial cells into a mixture of smaller RNA duplexes and then released into the cytoplasm of the target cells, resulting in modulation of gene expression in the target cells. The methods overcome the incompatibility between long strong dsRNA and mammalian cells by eliminating, or mitigating, the non-specific innate immune response. The eukaryotic cells can be mammalian cells or avian cells. The gene of interest can be a mammalian, avian, bacterial, eukaryotic, or viral gene. | 2011-05-12 |
| 20110111482 | High Viscosity Xanthan Polymer Preparations - Increasing the molecular length of xanthan polymer makes a higher viscosity xanthan composition. Xanthan with higher specific viscosity characteristics provides more viscosity at equivalent concentration in food, industrial and oilfield applications. Methods for increasing the viscosity of xanthan include inducing particular key genes and increasing copy number of particular key genes. | 2011-05-12 |
| 20110111483 | Optimizing Expression of Active Botulinum Toxin Type E - Nucleic acid molecules that comprise modified open reading frames providing increased expression of the encoded active BoNT/E in a heterologous cell, expression constructs and cells comprising such nucleic acid molecules and methods useful for expressing the encoding active BoNT/E from such nucleic acid molecules, expression constructs and cells. | 2011-05-12 |
| 20110111484 | REACTION JACKET FOR A PHOTOSYNTHETIC REACTOR AND RELATED PHOTOSYNTHETIC REACTOR - Reaction jacket for a photosynthetic reactor, configured to float on an expanse of water and to define a gas/liquid culture medium diphasic flow path between first and second openings of the reaction jacket, the jacket including two sheaths, outer and inner, respectively, at least partially made from a material transparent to light radiation, the inner sheath extending inside the outer sheath such that these sheaths define an inter-sheath space between them in fluid connection with the first opening of the jacket, where the outer sheath has an open proximal end and a closed distal end, and the inner sheath has an open proximal end in fluid connection with the second opening of the jacket and a distal end provided with at least one communication orifice between the inside of the inner sheath and the inter-sheath space. | 2011-05-12 |
| 20110111485 | SYSTEM AND PROCESS TO TREAT BIOMASS PILES WITH ENZYMES - A method for processing biomass including: conveying biomass to a pile of biomass on a platform; maintaining the biomass in the pile in a wetted condition, such that the biomass has a pH level in a predetermined pH range and a temperature in a predetermined temperature range; applying an enzyme to the biomass in the pile, wherein the enzyme extracts hemicelluloses from cellulosic fibrous material in the biomass; draining liquid from the pile of the biomass; removing the extracted hemicelluloses from the drained liquid, and returning to the pile at least a portion of the drained liquid after removal of the extracted hemicelluloses. | 2011-05-12 |
| 20110111486 | BIOREACTOR SYSTEMS AND DISPOSABLE BIOREACTOR - The present invention is in the field of cell bioreactors, and specifically in the field of disposable bioreactors. | 2011-05-12 |
| 20110111487 | MEHTOD AND APPARATUS FOR ASSAY BASED ON LIGHT DIFFRACTION - The present invention relates to a method and apparatus for detecting analytes in a medium, and more particularly the present invention relates to an assay based on light diffraction which appears or changes upon the binding of analytes to their specific receptors laid out in patterns on a substrate, which has high sensitivity due to the appropriate choice of such patterns. The present invention is based on the principle that the pattern of recognition elements, which gives rise to the diffraction of the incident light in a diffraction-based assay, can be chosen in such a way so as to facilitate detection, and to enhance the signal to be detected compared to known gratings such as parallel straight lines. In one aspect the substrate itself has a surface topography designed to enhance the diffraction pattern signals. In another aspect the substrate is a diffractive optic element having the analyte-specific receptors affixed to the optic element. In another aspect the diffractive optic element is used as a master stamp for producing patterns of analyte-specific receptors which give the signal enhancements. | 2011-05-12 |
| 20110111488 | BIOSENSOR - Disclosed herein is a biosensor, in which sensing electrodes are formed on an upper insulating substrate and a lower insulating substrate such that, using the sensing electrodes, a measuring device can determine whether a sample (e.g., blood) injected through a sample injection port is completely filled in a sample path and determine a time point at which the sample is injected and a time point at which the sample is completely filled. Therefore, it is possible to estimate the flow characteristics of the sample and the flow rate and use the estimated values to correct the measurement result, thus obtaining a more accurate measurement result. | 2011-05-12 |
| 20110111489 | SENSOR ADAPTER, METHOD FOR THE MANUFACTURE THEREOF, METHOD FOR THE USE OF A SENSOR IN THIS SENSOR ADAPTER AND BIOREACTOR WITH THIS SENSOR ADAPTER - A sensor adapter is described for the noninvasive positioning of a sensor, especially of an electrochemical sensor, in a medium. The sensor adapter comprises an accommodating channel, in which the sensor can be positioned and the one end region of which is closed off by a semipermeable membrane. Moreover, the sensor adapter comprises a hollow cylindrical sealing structure, which is disposed within the accommodating channel coaxially with the longitudinal axis of the latter and with which the sensor can be disposed gas tight adjacent to the semipermeable membrane. | 2011-05-12 |
| 20110111490 | LIGHT TRANSFORMATION PARTICLE AND PHOTOBIOREACTOR - A light transformation particle is provided. The light transformation particle of the invention includes a light-shifting layer containing at least one light-emitting material, wherein the light-emitting layer transforms ultraviolet light, yellow-green light, or infrared light to red-orange light or blue-violet light. The light transformation particle further includes a core layer and/or a shell layer. The present invention further provides a photobioreactor containing the light transformation particle of the invention. | 2011-05-12 |
